Oral rheumatoid arthritis therapy, Xeljanz, attempting for insurance as secondary treatment

An oral rheumatoid arthritis treatment ‘Xeljanz’ starts a move to recover its position as a practical secondary treatment.

According to the industry concerned on the 12^th, the Pfizer’s janus kinase(JAK) inhibitor Xeljanz(tofacitinib) which failed in the last year’s extension of the health insurance standard will be laid again in the Health Insurance Review & Assessment Service’s(HIRA) Health ...